The Pulmonary Radiation Toxicity drugs in development market research report provides comprehensive information on the therapeutics under development for Pulmonary Radiation Toxicity , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pulmonary Radiation Toxicity . Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pulmonary Radiation Toxicity and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Pulmonary Radiation Toxicity by five companies/universities/institutes. The top development phase for Pulmonary Radiation Toxicity is preclinical with three drugs in that stage. The Pulmonary Radiation Toxicity pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Pulmonary Radiation Toxicity pipeline products market are: Aqualung Therapeutics, New Amsterdam Sciences and BCN Biosciences.
The key targets in the Pulmonary Radiation Toxicity pipeline products market include Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12), NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.), and Substance P Receptor (Tachykinin Receptor 1 or NK 1 Receptor or NK1R or TACR1).
The key mechanisms of action in the Pulmonary Radiation Toxicity pipeline product include Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Inhibitor with two drugs in Preclinical. The Pulmonary Radiation Toxicity pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Pulmonary Radiation Toxicity pipeline products market including Small Molecule, and Monoclonal Antibody.
Pulmonary Radiation Toxicity overview
Radiation lung toxicity encompasses any lung toxicity induced by radiation therapy (RT). Damage to normal lung tissue in the individuals. There is a damage to normal lung tissue, to overcome this there is aa image-guided radiotherapy and the use of agents to reduce lung injury from radiation.
For a complete picture of Pulmonary Radiation Toxicity ‘s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
